Literature DB >> 27502508

Increased risk for secondary infections in trauma patients with viral reactivation.

Rebecca M Koch1,2, Matthijs Kox3,4, Janette C Rahamat-Langendoen5, Kim Timmermans3, Johannes G van der Hoeven3,4, Peter Pickkers3,4.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27502508     DOI： 10.1007/s00134-016-4474-5

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  4 in total

Review 1.  Post-infectious immune suppression: a new paradigm of severe infections.

Authors:  D Grimaldi; J F Llitjos; F Pène
Journal:  Med Mal Infect       Date:  2014-08-29       Impact factor: 2.152

2.  Epstein-Barr virus encoded interleukin-10 inhibits HLA-class I, ICAM-1, and B7 expression on human monocytes: implications for immune evasion by EBV.

Authors:  Shahram Salek-Ardakani; John R Arrand; Mike Mackett
Journal:  Virology       Date:  2002-12-20       Impact factor: 3.616

3.  Plasma levels of danger-associated molecular patterns are associated with immune suppression in trauma patients.

Authors:  Kim Timmermans; Matthijs Kox; Michiel Vaneker; Maarten van den Berg; Aaron John; Arjan van Laarhoven; Hans van der Hoeven; Gert Jan Scheffer; Peter Pickkers
Journal:  Intensive Care Med       Date:  2016-02-24       Impact factor: 17.440

4.  Reactivation of multiple viruses in patients with sepsis.

Authors:  Andrew H Walton; Jared T Muenzer; David Rasche; Jonathan S Boomer; Bryan Sato; Bernard H Brownstein; Alexandre Pachot; Terrence L Brooks; Elena Deych; William D Shannon; Jonathan M Green; Gregory A Storch; Richard S Hotchkiss
Journal:  PLoS One       Date:  2014-06-11       Impact factor: 3.240
  4 in total
  1 in total

Review 1.  Role of Mitochondria-Derived Danger Signals Released After Injury in Systemic Inflammation and Sepsis.

Authors:  Kiyoshi Itagaki; Ingred Riça; Barbora Konecna; Hyo In Kim; Jinbong Park; Elzbieta Kaczmarek; Carl J Hauser
Journal:  Antioxid Redox Signal       Date:  2021-05-25       Impact factor: 7.468
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.